Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18971858 | 1.00 | MGAM (0.43) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL1057822 | 1.00 | MGAM (0.43) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL2721040 | 0.92 | — | — | |
| SCHEMBL14389976 | 0.86 | MGAM (0.44) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL14389978 | 0.86 | MGAM (0.44) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL7790319 | 0.85 | MGAM (0.40) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL21072260 | 0.84 | MGAM (0.43) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL7782689 | 0.84 | MGAM (0.43) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL3036111 | 0.84 | MGAM (0.43) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL12353793 | 0.84 | MGAM (0.43) | MGAMGAASIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236632-A1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2025-07-24 | — | — | US | disclosed |
| EP-3922635-A1 | BETA-LACTAMASE INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-2928898-B1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS INC (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10669290-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2020-06-02 | — | — | US | disclosed |
| EP-3388423-B1 | NK1 RECEPTOR ANTAGONIST | KISSEI PHARMACEUTICAL (JP) | 2020-05-27 | — | — | EP | disclosed |
| US-10399949-B2 | NK1 receptor antagonist | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2019-09-03 | — | — | US | disclosed |
| US-20190225628-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-25 | — | — | US | disclosed |
| US-20190002414-A1 | NK1 RECEPTOR ANTAGONIST | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2019-01-03 | — | — | US | disclosed |
| US-20180194783-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2018-07-12 | — | — | US | disclosed |
| US-9828391-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2017-11-28 | — | — | US | disclosed |
| US-8759365-B2 | Organic compounds | NOVARTIS AG (CH) | 2014-06-24 | — | — | US | disclosed |
| US-20140171390-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2014-06-19 | — | — | US | disclosed |
| WO-2014089365-A1 | BETA-LACTAMASE INHIBITORS | VENATORX PHARMACEUTICALS, INC (US) | 2014-06-12 | — | — | WO | disclosed |
| CN-101878199-B | 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis | NOVARTIS AG | 2013-09-18 | — | — | CN | disclosed |
| EP-2404901-A1 | 1,2-Disubstituted 4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis | Novartis AG (CH) | 2012-01-11 | — | — | EP | disclosed |
| EP-2229356-B1 | 1,2-DISUBSTITUTED-4-BENZYLAMINO-PYRROLIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLI PIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2011-10-12 | — | — | EP | disclosed |
| US-20100311750-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-12-09 | — | — | US | disclosed |
| CN-101878199-A | 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis | NOVARTIS AG | 2010-11-03 | — | — | CN | disclosed |
| EP-2229356-A1 | 1,2-DISUBSTITUTED-4-BENZYLAMINO-PYRROLIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLI PIDEMIA OR ARTERIOSCLEROSIS | Novartis AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009071509-A1 | 1,2-DISUBSTITUTED-4-BENZYLAMINO-PYRROLIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLI PIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194783-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | MGAM 1/4885GAA 2/4885SI 32/4885 |
| US-20250236632-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | MGAM 1/4885GAA 2/4885SI 32/4885 |
| US-20190225628-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | MGAM 1/4885GAA 2/4885SI 32/4885 |
| US-10669290-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | MGAM 1/4885GAA 2/4885SI 32/4885 |
| US-20190002414-A1 | NK1 RECEPTOR ANTAGONIST | TACR1, TACR2, GRPR | MGAM 4808/4885GAA 4798/4885SI 2761/4885 |
| US-20140171390-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | MGAM 1/4885GAA 2/4885SI 32/4885 |
| US-20100311750-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | MGAM 3551/4885GAA 641/4885SI 3642/4885 |
| US-10399949-B2 | NK1 receptor antagonist | TACR1, TACR2, GRPR | MGAM 4808/4885GAA 4798/4885SI 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.